Company intelligence / Profile preview

Suzhou Zenith Vascular Co., Ltd.

Ownership: Private
Development stage: Commercial

Overview

The company has launched innovative thrombectomy and stent systems for vascular diseases. Its SWAM Peripheral Thrombectomy Solution was first domestically launched in China in early 2024. The company’s stent retriever devices are under clinical study for acute pulmonary embolism, expected to complete by January 2025. The Zenith Carotid Stent System is under special review by Chinese regulators as an innovative medical device.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Suzhou Zenith Vascular Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Zenith Vascular Co., Ltd..

Explore the full profile